Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Yu‐Luan Chen"'
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 2, Pp n/a-n/a (2024)
Abstract Ulotaront (SEP‐363856) is a TAAR1 agonist, with 5‐HT1A agonist activity, currently in clinical development for the treatment of schizophrenia. In vitro studies indicate ulotaront is an OCT2‐specific inhibitor with IC50 of 1.27 μM. The
Externí odkaz:
https://doaj.org/article/6ab6e839dc2b4529b1b2f4f221971a6c
Autor:
Yu-Luan Chen, Hironobu Tsukada, Snezana Milanovic, Lei Shi, Yan Li, Yongcai Mao, Kenneth S. Koblan, Gerald R. Galluppi
Publikováno v:
Neurology and Therapy, Vol 12, Iss 3, Pp 815-832 (2023)
Abstract Introduction Ulotaront (SEP-363856), a dual trace animeassociated receptor 1 (TAAR1) and 5-HT1A receptor agonist, is in phase 3 clinical development for the treatment of schizophrenia. This study evaluated the comparative bioequivalence (BE)
Externí odkaz:
https://doaj.org/article/e6aa69b4bb0544e5afb9f1d477d9b8a5
Autor:
Siqing Fu, David E. Piccioni, Hongtao Liu, Rimas V. Lukas, Santosh Kesari, Dawit Aregawi, David S. Hong, Kenichiro Yamaguchi, Kate Whicher, Yi Zhang, Yu-Luan Chen, Nagaraju Poola, John Eddy, David Blum
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract WT2725 is a Wilms’ tumor gene 1 (WT1)-derived-oligopeptide vaccine designed to induce WT1-specific cytotoxic T-lymphocytes against WT1+ tumors in human leukocyte antigen (HLA)-A*0201+ and/or HLA-A*0206+ patients. Here, we report the result
Externí odkaz:
https://doaj.org/article/60746137df784b578782dc3342f39baf
Autor:
Guangqing Xiao, Yu-Luan Chen, Nina Dedic, Linghong Xie, Kenneth S. Koblan, Gerald R. Galluppi
Publikováno v:
Pharmaceutical Research. 39:837-850
Purpose Ulotaront (SEP-363856) is a TAAR1 agonist with 5-HT1A agonist activity currently in clinical development for the treatment of schizophrenia. The objectives of the current study were to characterize the in vitro ADME properties, preclinical PK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::597b31b1ce1d071bca5b9e820fd5df8f
https://doi.org/10.1007/s11095-022-03267-1
https://doi.org/10.1007/s11095-022-03267-1
Publikováno v:
Drug Metabolism and Bioanalysis Letters. 15:38-50
Objective: The study aims to explore the human in vivo metabolism of SEP-227900 (4H-furo[3, 2-b] pyrrole-carboxylic acid, m.w 151.03), a D-amino-acid oxidase (DAAO) inhibitor, by using plasma and urine samples from first-in-human study. Methods: The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::baeb0ab5226642b60475d5c0ba58b6f9
https://doi.org/10.2174/1872312815666220302161959
https://doi.org/10.2174/1872312815666220302161959
Publikováno v:
Bioanalysis. 13:959-968
Aim: Glycopyrrolate (GLY) has been widely used to treat chronic obstructive pulmonary disease (COPD). Recent technical advancement significantly improves the drug delivery efficiency. In a clinical dose-range determination study via electronic nebuli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3740665fdd8898103fe459b7590f4f56
https://doi.org/10.4155/bio-2021-0037
https://doi.org/10.4155/bio-2021-0037
Autor:
Lei Shi, Zhong-Ping John Lin, Soujanya Sunkaraneni, Yu-Luan Chen, John Eddy, Armand Gatien Ngounou Wetie, Weimin Wang
Publikováno v:
The Journal of Applied Laboratory Medicine. 5:41-53
BackgroundThe development of more efficient drug delivery devices for ciclesonide inhalation products requires an ultrasensitive bioanalytical method to measure systematic exposure of ciclesonide (CIC) and its active metabolite desisobutyryl-cicleson
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27f0e82eeb82d176254a42c39b5e6a1c
https://doi.org/10.1373/jalm.2019.029397
https://doi.org/10.1373/jalm.2019.029397
Autor:
Kate Whicher, Santosh Kesari, Hongtao Liu, Rimas V. Lukas, David S. Hong, Dawit Aregawi, Siqing Fu, David Piccioni, David Blum, Kenichiro Yamaguchi, Yi Zhang, John Eddy, Yu-Luan Chen, Nagaraju Poola
Publikováno v:
Scientific Reports
Scientific reports, vol 11, iss 1
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific reports, vol 11, iss 1
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
WT2725 is a Wilms’ tumor gene 1 (WT1)-derived-oligopeptide vaccine designed to induce WT1-specific cytotoxic T-lymphocytes against WT1+ tumors in human leukocyte antigen (HLA)-A*0201+ and/or HLA-A*0206+ patients. Here, we report the results of a ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7bf47004af0f6ea527d2785874e6907
https://doi.org/10.1038/s41598-021-01707-3
https://doi.org/10.1038/s41598-021-01707-3
Publikováno v:
Drug metabolism and bioanalysis letters. 15(1)
The study aims to explore the human in vivo metabolism of SEP-227900 (4H-furo[3, 2-b] pyrrole-carboxylic acid, m.w 151.03), a D-amino-acid oxidase (DAAO) inhibitor, by using plasma and urine samples from first-in-human study.The human plasma and urin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5ffff45667d2e13a8f60f6302e90f7d8
https://pubmed.ncbi.nlm.nih.gov/35236276
https://pubmed.ncbi.nlm.nih.gov/35236276
Publikováno v:
Journal of Applied Bioanalysis, Vol 5, Iss 2, Pp 20-33 (2019)
OBJECTIVES: Develop and validate a simple and rapid LC-MS/MS method for plasma D-serine measurement to support clinical development of a potential D-amino-acid oxidase (DAAO) inhibitor. METHODS: Calibration standards in phosphate buffered saline (PBS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89479fdeeb7f06e81bec7f7c568047e4
https://doi.org/10.17145/jab.19.005
https://doi.org/10.17145/jab.19.005